Notable FDA

FDA Determines Regulatory Review Period for Andembry to Support Patent Extension

FDA's determination of the regulatory review period for Andembry enables patent term restoration under the Hatch-Waxman Act, directly impacting commercial exclusivity for this biological product. The Food and Drug Administration (FDA) has determined the regulatory review period for Andembry, a...

The deep analysis — cross-item commentary and how this topic has evolved — is part of SignalHealth Pro.

Start a 14-day Pro trial — $9/month

Sources — verify every claim

Health and Human Services Department, Food and Drug Administration · Determination of Regulatory Review Period for Purposes of Patent Extension; ANDEMBRY · Sep 9

Trust record

Agent curated